Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 94 filers reported holding Y-MABS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $497,307 | -21.3% | 91,249 | -1.9% | 0.03% | -11.1% |
Q2 2023 | $631,619 | +40.9% | 93,022 | +4.0% | 0.04% | +44.0% |
Q1 2023 | $448,295 | +5.5% | 89,480 | +2.7% | 0.02% | +4.2% |
Q4 2022 | $424,999 | -67.5% | 87,090 | -3.9% | 0.02% | -68.4% |
Q3 2022 | $1,307,000 | -6.0% | 90,665 | -1.3% | 0.08% | +13.4% |
Q2 2022 | $1,390,000 | +29.4% | 91,898 | +1.7% | 0.07% | +55.8% |
Q1 2022 | $1,074,000 | -21.5% | 90,375 | +7.1% | 0.04% | -12.2% |
Q4 2021 | $1,368,000 | -51.7% | 84,395 | -15.0% | 0.05% | -53.3% |
Q3 2021 | $2,834,000 | -13.4% | 99,291 | +2.6% | 0.10% | -9.5% |
Q2 2021 | $3,271,000 | +7.1% | 96,774 | -4.2% | 0.12% | +16.0% |
Q1 2021 | $3,055,000 | -38.9% | 101,028 | +0.0% | 0.10% | -43.2% |
Q4 2020 | $5,000,000 | +37.7% | 100,994 | +6.8% | 0.18% | +20.5% |
Q3 2020 | $3,630,000 | +30.6% | 94,567 | +47.0% | 0.15% | +22.7% |
Q2 2020 | $2,779,000 | +67.3% | 64,326 | +1.1% | 0.12% | +28.0% |
Q1 2020 | $1,661,000 | +34.4% | 63,628 | +60.8% | 0.09% | +121.4% |
Q4 2019 | $1,236,000 | – | 39,566 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 191,176 | $1,041,909 | 4.24% |
Sofinnova Investments, Inc. | 2,194,278 | $11,958,815 | 0.75% |
DENALI ADVISORS LLC | 85,900 | $468,155 | 0.16% |
Polar Capital Holdings Plc | 2,103,298 | $11,462,974 | 0.08% |
Soleus Capital Management, L.P. | 157,182 | $856,642 | 0.08% |
GSA CAPITAL PARTNERS LLP | 137,299 | $748 | 0.06% |
Caligan Partners LP | 23,321 | $127,099 | 0.06% |
Corton Capital Inc. | 12,244 | $66,730 | 0.03% |
RICE HALL JAMES & ASSOCIATES, LLC | 91,249 | $497,307 | 0.03% |
CIM INVESTMENT MANAGEMENT INC | 15,313 | $83,456 | 0.03% |